Leerink Swann Resumes CLOVIS ONCOLOGY (CLVS) at Outperform, Notes High Risk/Reward
Tweet Send to a Friend
Leerink Swann resumed coverage on CLOVIS ONCOLOGY (NASDAQ: CLVS) with a Outperform rating and price target of $25.00.
"Near ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
"Near ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
